What is LUCD's current stock price?

LUCD (Lucid Diagnostics Inc.) is currently trading at $1.07 with a market cap of $109.5M.

What sector is Lucid Diagnostics Inc. in?

Lucid Diagnostics Inc. (LUCD) operates in the Healthcare sector, specifically in the Medical - Devices industry.

Is LUCD a good stock to buy?

Analysts have a Buy consensus on LUCD with a price target of $2.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

LUCD Lucid Diagnostics Inc.

Healthcare

$1.07+7.00%ClosedMarket Cap: $109.5M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

27.27

P/S

21.32

EV/EBITDA

-2.56

DCF Value

$-2.86

FCF Yield

-42.4%

Div Yield

0.0%

Margins & Returns

Gross Margin

-40.0%

Operating Margin

-959.6%

Net Margin

-876.7%

ROE

-370.2%

ROA

-132.1%

ROIC

-159.9%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$1.3M	$-13.9M	$—
Q4 null	$1.5M	$-16.3M	$—
FY null	$4.7M	$-58.0M	$—
Q3 null	$1.2M	$-10.4M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$2.00

Target (Median)

$2.00

Target Range

$2.00 - $2.00

2 Strong Buy3 Buy0 Hold0 Sell0 Strong Sell

BTIGBuy

2026-05-15

Maxim GroupBuy

2026-05-15

Ascendiant CapitalBuy

2026-04-09

BTIGBuy

2026-03-30

NeedhamBuy

2026-03-26

Trading Activity

Insider Trades

View All

Matheis Dennisdirector

BuyThu May 21

Lee Victoria Tou-hoofficer: Chief Medical Officer

SellFri Apr 24

Lee Victoria Tou-hoofficer: Chief Medical Officer

SellMon Apr 13

White Debradirector

SellTue Feb 24

Sparks Ronald Mdirector

SellTue Feb 24

Latest News

Lucid Diagnostics Inc. (LUCD) Q4 2025 Earnings Call TranscriptSeeking Alpha · Thu Mar 26

Company Info

Sector

Healthcare

Industry

Medical - Devices

Country

Exchange

—

Beta

1.10

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

Peers

APYX

AVR

IRD